A three-dimensional assay for measurement of viral-induced oncolysis

Cancer Gene Therapy

Volumn 14, Issue 4, 2007, Pages 421-430

  Lam, J T ^a   Hemminki, A ^b,c   Kanerva, A ^b,c   Lee, K B ^d   Blackwell, J L ^e   Desmond, R ^f   Siegal, G P ^g,h   Curiel, D T ^g,h  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d Inje University College of Medicine   (South Korea)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g University of Alabama at Birmingham   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adenovirus; Oncolytic virus; Ovarian cancer; Replication competent viruses; Spheroid

Indexed keywords

LUCIFERASE; ONCOLYTIC VIRUS;

ADENOVIRUS; ANALYTIC METHOD; ANIMAL CELL; ARTICLE; CANCER CELL DESTRUCTION; CANCER THERAPY; CELL CULTURE; CELL DEATH; CONTROLLED STUDY; CYTOLYSIS; DIAGNOSTIC VALUE; EMBRYO; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; LABORATORY TEST; MOLECULAR MODEL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPHEROID CELL; TREATMENT OUTCOME; TUMOR CELL;

ADENOVIRIDAE; BIOLOGICAL ASSAY; HUMANS; LUCIFERASES; ONCOLYTIC VIRUSES; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

ADENOVIRIDAE; REPLICATION COMPETENT VIRUSES;

EID: 33947243583     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701028     Document Type: Article

References (31)

1. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles,risk management and future directions. Nat Med 2001; 7: 781-787.
2. Kanerva A, Hemminki A. Modified adenoviruses for cancer gene therapy. Int J Cancer 2004; 110: 475-480.
3. Theys J, Barbe S, Landuyt W, Nuyts S, Van Mellaert L, Wouters B et al. Tumor-specific gene delivery using genetically engineered bacteria. Curr Gene Ther 2003; 3: 207-221.
4. Puumalainen AM, Vapalahti M, Agrawal RS, Kossila M, Laukkanen J, Lehtolainen P et al. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 1998; 9: 1769-1774.
5. Lamfers ML, Hemminki A. Multicellular tumor spheroids in gene therapy and oncolytic virus therapy. Curr Opin Mol Ther 2004; 6: 403-411.
6. Kanerva A, Hemminki A. Adenoviruses for treatment of cancer. Ann Med 2005; 37: 33-43.
7. Saukkonen K, Hemminki A. Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 2004; 4: 683-696.
8. Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM et al. Infectivity enhanced,cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 2003; 125: 1203-1218.
9. Kanerva A, Bauerschmitz GJ, Yamamoto M, Lam JT, Alvarez RD, Siegal GP et al. A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Therapy 2004; 11: 552-559.
10. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001; 7: 120-126.
11. Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8: 449-458.
12. Bauerschmitz GJ,Lam JT, Kanerva A,Suzuki K, Nettelbeck DM,Dmitriev I et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62: 1266-1270.
13. Kanerva A, Zinn KR, Peng KW, Ranki T, Kangasniemi L, Chaudhuri TR et al. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Therapy 2005; 12: 87-94.
14. Kirn D. Clinical research results with dl1520 (Onyx-015),a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Therapy 2001; 8: 89-98.
15. Lam JT, Bauerschmitz GJ, Kanerva A, Barker SD, Straughn JM, Wang M et al. Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Therapy 2003; 10: 377-387.
16. Lam JT, Kanerva A, Bauerschmitz GJ, Takayama K, Suzuki K, Yamamoto M et al. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. J Gene Med 2004; 6: 1333-1342.
17. Schafer H, Schafer A, Kiderlen AF, Masihi KN, Burger R. A highly sensitive cytotoxicity assay based on the release of reporter enzymes,from stably transfected cell lines. J Immunol Methods 1997; 204: 89-98.
18. Hemminki A, Belousova N, Zinn KR, Liu B, Wang M, Chaudhuri TR et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 2001; 4: 223-231.
19. Hemminki A,Zinn KR,Liu B,Chaudhuri TR,Desmond RA,Rogers BE et al. In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst. 2002; 94: 741-749.
20. Krasnykh V,Belousova N,Korokhov N,Mikheeva G, Curiel DT. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001; 75: 4176-4183.
21. Mittereder N,March KL,Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
22. Kunz-Schughart LA, Kreutz M, Knuechel R. Multicellular spheroids: a three-dimensional in vitro culture system to study tumour biology. Int J Exp Pathol 1998; 79: 1-23.
23. Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001; 61: 813-817.
24. Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R, Curiel DT. Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res 2001; 61: 6377-6381.
25. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-280.
26. Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002; 5: 695-704.
27. Grill J, Lamfers ML, van Beusechem VW, Dirven CM, Pherai DS, Kater M et al. The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol Ther 2002; 6: 609-614.
28. Lamfers ML, Grill J, Dirven CM, Van Beusechem VW, Geoerger B, Van Den Berg J et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002; 62: 5736-5742.
29. Ryu R, Shin Y, Choi JW, Min W, Ryu H, Choi CR et al. Depletion of intracellular glutathione mediates zinc-induced cell death in rat primary astrocytes. Exp Brain Res 2002; 143: 257-263.
30. Coley HM,Lewandowicz G, Sargent JM,Verrill MW. Chemosensitivity testing of fresh and continuous tumor cell cultures using lactate dehydrogenase. Anticancer Res 1997; 17: 231-236.
31. Wood KV. Recent Advances and Prospects for Use of Beetle Luciferase as Genetic Reports. John Wiley and Sons; Chichester,1991, 11p.